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1 Introduction
Premature delivery is an important obstetrical
complication associated with increase perinatal
mortality and morbidity. There is good evidence
that prostaglandins play an important role in the
pathogenesis of premature labor [14]. The non-
steroid anti-inflammatory agent indomethacin, is a
potent inhibitor of prostaglandin biosynthesis in
the body and it is also an established fact that
contractions may be inhibited by indomethacin
[20]. In first part of the study we have shown in a
very large uncontrolled group of patients the effi-
cacy and safety of the drug in arresting prema-
ture labor, the same as others [4, 8, 25, 29].
The purpose of the second part of the study was
to test in a controlled double-blind fashion the
efficacy of indomethacin in suppressing the prema-
ture labor.
2 Material and methods
Patients included in the trial were between 25—35
weeks gestation who presented with painful,
regular uterine contractions occurring at intervals
of two or more contractions in 10 minutes,
recorded for at least 30 minutes by external toco-
graphy, or contractions accompanied by efface-
ment and/or dilation of the cervix at least 1—2 cm,
but not more than 4 cm.
The patients were informed about the aim of the
investigation. All patients have had ultrasonic
examination before treatment. We excluded
patients with pre-eclampsia, diabetes mellitus,
twins, cardiac disease, antepartum hemorrhage,
ruptured membranes, intra-uterine infections or
intra-uterine growth retardation. Indomethacin or
placebo were allocated at random. The code key
was not available to the investigators before com-
pletion of the study. The indomethacin group
included 18 patients and the placebo group also
included 18 patients. After an initial registration
of contractions for 30 minutes, indomethacin or
placebo was begun. Treatment consisted of a rectal
suppository of 100 mg and then capsules of 25 mg
4 times daily for 24 hours. If uterine contractions
continued after the insertion of the first supposi-
tory, the patient received an additional 100mg
suppository (from the same envelope) after 1 hour,
and then the treatment was continued orally. The
total dosage of indomethacin was 200—300 mg in
24 hours. If there were further indications of
premature delivery and progressive dilation of the
cervix 2 hours after the first suppository, this was
considered as a treatment failure and other
therapy for cessation of premature labor was
given. The uterine activity was recorded with a
cardiotocograph.
The matemal heart rate, maternal blood pressure
and fetal heart rate were recorded. During hospi-
talization, both the indomethacin and placebo
treated patients were kept at bed rest. If they had
no contractions after the completion of treatment
during 3 days, they were discharged from the
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hospital. The treatment was considered successful
if labor was arrested and delivery was delayed for
more than 7 days. It was considered to be of
moderate value if labor was arrested from 48 hours
to 7 days, and considered unsuccessful if delivery
took place within 48 hours. The criterion for
prematurity was a birth age of less than 37 week
gestation confirmed at delivery using the
DUBOWITZ assessment scale [6]. The pediatrician
examined each newborn immediately after deliv-
ery, during hospitalization and in follow up of
6 months. There was no significant difference
between the 2 groups in respect to age, parity arid
gestational age (Tab. I). The delay between the
initiation of the indomethacin and placebo
therapy and the delivery, weight and maturity of
the newborn were the criteria for evaluating the
differences between the two treatments.
3 Results
Effect of treatment is summarized in Tab. II.
In the indomethacin group treatment was success-
ful (contractions stopped completely for more
than 1 week) in 15 of 18 patients (83.3%), of
moderate value (3—7 days) in 2 of 18 patients
(11.1%) and unsuccessful (delivery within 48
Tab. II. Effect of treatment.
hours) in 1 of 18 patients (5.6%). In the placebo
group the results were successful in 3 of 18
patients (16.6%), of moderate value in 1 of
18 patients (5.6%) and unsuccessful in 14 of 18
patients (77.8%).
Among these 14 patients with unseccessful results,
8 mothers received alternative treatment (ritodrine)
but 5 were delivered within 24 hours and 3 within
48 hours. The clinical outcome is presented in
Tab. III. The mean duration of pregnancy for the
indomethacin patients (36.4 weeks ± 0.7) was
significantly greater than that for the placebo
group (31.2 weeks ± 0.7) (p < 0.001). In the indo-
methacin group 3 newborns weighed less than
2500 g (mean birth weight for the group
2833 g ± 117g) compared with 15 newborns in the
placebo group (mean birth weight for the group
2028 g ± 123 g). The mean 1 minute APGAR score
in the indomethacin treated group was 9.3 ± 0.2
while in the placebo treated group it was only
7.8 ± 0.5 (p< 0.01).
Respiratory distress syndrome was diagnosed in
one infant in the indomethacin group and 4 in the
placebo group. One infant in the indomethacin
group (weight 1810g) and 2 infants in the placebo
group (weight 600 and 1450 g) died from respira-
tory distress syndrome. The autopsy showed
typical pulmonary atelectasis and hyaline mem-
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Gestational week Birth weight APGAR score
At therapy At delivery* (gm)* (1 min)+
30.3 ±0.7 36.4 ±0.7 2833 ± 117 9.3 ± 0.2
30.7 ±0.8 31. 2 ±0.7 2028 ± 123 7.8 ± 0.5
*p<0.001
+ p <0.01
branes in these 3 infants. There was no evidence of 22.2% of the placebo group. The lower percentage
premature closure of the ductus arteriosus or pul- can be explained by the strict criteria that we used
monary hypertension. The remaining children for definition of premature labor. Using similar
were normal at follow-up examination. criteria, NlEBYL et al. [18] found that patients
Cesarean section was performed in 1 patient in the who failed to respond to placebo has a higher
indomethacin group because of breech presenta- mean serum prostaglandin F2a metabolite (PGFM)
tion in the first delivery and in 1 patient in the than the rest of the placebo group. The author
placebo group because of prolapse of the cord, pointed to a possible predictive value of this
Minor side effects as nausea, vomiting and vertigo measurements.
were seen in 2 mothers in the indomethacin group. Looking from the other side the patient who
In the placebo group there were no side effects, respond to placebo had the lower mean PGFM
Side effects were not significantly severe to level which may suggest that these patients were
warrant discontinuance of treatment. There were not in true labor. It is evident that in part of the
no differences during and after therapy in either cases in which we treat what we call premature
maternal blood pressure, or maternal and fetal labor all we are doing is stopping the uterine con-
heart rate. tractions of a false labor. This problem, of whom
to treat, will be solved only with more strict and
objective criteria.
4 Discussion Mean duration of pregnancy, mean birth weight
and the number of mature newborns in the indo-
Any tocolytic agent can be used only when it methacin group was significantly greater than that
needed and after its efficacy and safety to both in the placebo group and the incidence of respira-
mother and fetus has been proved. We believe that tory distress syndrome was higher in infants of
safety of indomethacin has been proved in the first mother treated with placebo. Similar results were
part of the study comprising 297 cases. We tried to obtained in study conducted by NlEBYL et al.
test the efficacy of the drug in the second part of [18]. Although no conclusions can be drawn about
the study using randomized controlled double- safety from such a small number of exposed
blind study. It was already shown that premature babies, considering also the first part of the study,
labor may be arrested with placebo in 48% of it must be stressed that no deleterious effect on
patients [28]. This fact can be explained by cardiovascular, renal or coagulation system could
improper criteria for diagnosis of premature labor be shown to be attributed by the indomethacin.
with part of the patients not being at labor, or that The results of this part of the study indicate that
bed rest alone can be effective treatment in some indomethacin is a potent inhibitor of premature
cases. In the present study labor was arrested in labor.
Summary
In the etiology of premature labor prostaglandins fulfill indomethacin on premature labor was studied in a pros-
a significant role. It is known that indomethacin is a pective randomized double-blind study in 36 patients,
strong inhibitor of prostaglandin synthesis. The effect of Eighteen patients received indomethacin and eighteen
J. Perinat. Med. 12 (1984) .
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received placebo. 200-300 mg of indomethacin was the
total dosage in a 24 hours period. The activity of the
uterus was monitored with a cardiotocograph. The mean
duration of pregnancy and the mean birth weight in indo-
methacin group (36.4 weeks, 2833 g) were both signifi-
cantly greater (p < 0.001) than that in placebo group
(31.2 weeks, 2028 g). In the indomethacin group 3 chil-
dren weighed less than 2500 g compared with 14 in
placebo group. In 15 of 18 indomethacin treated patients
(83.3%) premature labor was arrested after indomethacin
treatment compared with 4 of 18 in the placebo group
(22.2%). The indomethacin group had a mean 1 minute
APGAR score of 9.3 ± 0.2 whereas the placebo group
showed a score of 7.8 ± 0.5 (p < 0.01). Three infants died
Keywords: Indomethacin, premature labor, prostaglandin
from respiratory distress syndrome; one in the indo-
methacin group (1810g) and two in the placebo group
(600 and 1450 g). Autopsies in the infants demonstrated
a typical picture of pulmonary atelectasis and hyaline
membranes.
There was no evidence of premature closure of the ductus
arteriosus or pulmonary hypertension. 2 mothers in the
indomethacin group suffered minor discomfort i.e.
nausea, vomiting and vertigo. In both groups, no changes
were noted, either during or after therapy in maternal
blood pressure or maternal and fetal heart rate. Indo-
methacin was shown to be significantly more effective
than placebo in inhibiting premature labor.
synthetase inhibitor, uterine contractions.
Zusammenfassung
Weitere Untersuchungen zur Hemmung vorzeitiger Wehen
durch Indometacin — Teil II - Doppelblindstudie
In der Ätiologie vorzeitiger Wehen spielen Prostaglandine
eine bedeutende Rolle. Es ist bekannt, daß Indometacin
ein starker Hemmstoff der Prostaglandinsynthese ist. Wir
untersuchten die Wirksamkeit von Indometacin bei vor-
zeitigen Wehen in einer prospektiven, randomisierten
Doppelblindstudie bei 36 Patientinnen. 18 Frauen erhiel-
ten Indometacin und 18 ein Placebo. Die Gesamtdosis
betrug 200-300 mg Indometacin über 24 Stunden. Die
Uteruskontraktionen wurden mit einem Kardiotoko-
graphen aufgezeichnet. In der Indometacin-Gruppe lag die
durchschnittliche Schwangerschaftsdauer und das durch-
schnittliche Geburtsgewicht signifikant höher als in der
Placebo-Gruppe (36,4 Wochen, 2833 g bzw. 31,2 Wochen,
2028g; p < 0,001). In der Indometacin-Gruppe wogen
3 Neugeborene unter 2500 g im Vergleich zu 14 Kindern
in der Placebo-Gruppe. Bei 15 der 18 mit Indometacin
behandelten Patientinnen (83,3%) konnten die Wehen
gehemmt werden; in der Placebo-Gruppe sistierten die
Wehen in 4 Fällen (22,2%). In der Indometacin-Gruppe
betrug der APGAR-Score l Minute pp. durchschnittlich
9,3 ± 0,2, während er in der Placebo-Gruppe bei 7,8 ± 0,5
lag (p < 0,01). 3 Kinder starben an einem RDS: l aus der
Indometacin-Gruppe (1810g) und 2 aus der Placebo-
Gruppe (600 g bzw. 1450 g). Bei der Sektion dieser
Kinder zeigte sich das typische Bild pulmonaler Atelek-
tasen und hyaliner Membranen. Es fanden sich keine
Hinweise auf einen vorzeitigen Verschluß des Ductus
arteriosus oder auf eine pulmonale Hypertension. Zwei
Frauen in der Indometacin-Gruppe hatten Beschwerden
wie Übelkeit, Erbrechen und Schwindelgefühle. In beiden
Gruppen konnten weder während noch nach der Therapie
Veränderungen hinsichtlich des Blutdrucks und der Herz-
frequenz bei der Patientin beobachtet werden; auch die
fetale Herzfrequenz blieb unverändert. Wir konnten
zeigen, daß Indometacin bei der Hemmung vorzeitiger
Wehen signifikant effektiver wirkt als ein Placebo.
Schlüsselwörter: Indometacin, Prostaglandinsynthetase-Hemmstoff, Uteruskontraktionen, vorzeitige Wehen.
Resume
Etude complementaire du blocage de l'accouchement
premature par Findometacine — II. — Etude en double
aveugle
Les prostaglandines revetent un role significatif dans
l'etiologie de l'accouchement premature. II est connu que
l'indometacine est un inhibiteur puissant de la synthese
des prostaglandines. L'effet de l'indometacine sur
l'accouchement premature a ete etudie dans une etude
prospective randomisee en double aveugle portant sur
36 patientes. ISpatientes ont regu de l'indometacine et
18 ont regu un placebo. La dose totale quotidienne
d'indometacine a ete de 200 ä 300 mg. L'activite uterine
a ete surveillee ä l'aide d'un cardiotocographe. La duree
moyenne de la grossesse et le poids de naissance moyen
(36,4 semaines, 2833g) ont ete de fagon significative
(p < 0,001) plus grands dans le groupe indometacine que
dans le groupe placebo (31,2 semaines, 2028 g). 3 enfants
pesaient moins de 2500 g dans le groupe indometacine
contre 14 dans le groupe placebo. Le travail premature a
Mots-cles: Accouchement premature, contractions
prostaglandines.
ete stoppe chez 15 des 18 patientes traitees par indo-
metacine (83,3 %) contre 4 sur 18 dans le groupe placebo
(22,2%). Le score d'APGAR ä l minute dans le groupe
indometacine etait de 9,3 ± 0,2, alors que dans le groupe
placebo il etait de 7,8 ± 0,5 (p < 0,01). Trois sont morts
d'un syndrome de detresse respiratoire; 1'un dans le
groupe indometacine (1810g) et deux dans le groupe
placebo (600 et 1450g). L'autopsie de ces enfants a
montre un tableau typique d'atelectasie pulmonaire et de
membranes hyalines.
II n'y a pas eu de fermeture prematuree du canal arteriel
ni d'hypertension pulmonaire. Deux meres dans le groupe
indometacine ont presente des troubles minimes ä savoir
nausees, vomissements et vertiges. Dans les 2 groupes, on
n'a pas observe de modification de la pression arterielle
maternelle ou du rythme cardiaque foetal ni pendant ni
apres le traitement. II est montre que rindometacine est
de fagon significative plus efficace qu'un placebo dans
l'inhibition de Faccouchement premature.
uterines, indometacine, inhibiteur de la synthese des
J. Perinat. Med. 12 (1984)
Zuckcrman et al., Indomcthacin, part II 29
Bibliography
|11 AIKEN, J. W.: Aspirin and indomethacin prolong
parturition in rats. Nature 240 (1972) 21
[2]ARCILLA, R. A., O. G. THILENIUS, K. RANNI-
GER: Congestive heart failure from suspected ductal
closure in utero. J. Pediat. 75 (1969) 74
(3) BENEDETTI.T.J.: Maternal complications of paren-
teral and sympathomimetic therapy for premature
labor. Amer.J. Obstet.Gynec. 145 (1983) 1[4] CABALLERO, Α., A.TEJERINA, Υ.A. DOMINGUEZ:
The prevention of premature labor by indomethacin.
Rev. Franc. Gynec. Obstet. 73 (1978) 45
[5] COLLINS, E., G.TURNER: Salicylates and preg-
nancy. Lancet II (1973) 1494
(61 DUBOWITZ, L. M. S., V. DUBOW1TZ, C. GOLD-
BERG: Clinical assessment of gestational age in the
newborn infant. J. Pediat. 77 (1970) 1
[7J FUCHS, F., A. R. FUCHS, V. F. POBLETE JR., A.
RISK: Effects of alcohol on threatened premature
labor. Amer. J. Obstet. Gynec. 99 (1967) 637
[81 HALLE, H., P. HENGST: Additional tocolysis via
inhibition of prostaglandin synthetase with indo-
methacin. Z. Geburtsh. Perinat. 182 (1978) 367
[91 JOHNSON, J.W. C, K.L.AUSTIN, G.S.JONES,
G.H.DAVIS, T.M.KING: Efficacy of 17-hydroxy-
progesterone caproate in the prevention of prema-
ture labor. N. Engl. J. Med. 296 (1975) 675
[101 KARIM, S. M. M., J. DEVLIN: Prostaglandin content
of amniotic fluid during pregnancy and labour. J.
Obstet. Gynaec. Brit. Cwlth. 74 (1967) 230
[11J KARIM, S. M. M., R. R. TRUSSEL, R. C. PATEL,
K. HILLIER: Response of pregnant human uterus to
prostaglandin F2a - induction of labour. Br. Med. J.
4(1968)621
[121 KARIM, S. M. M., K. HILLIER, R. R. TRUSSEL,
R. C. PATEL: Induction of labour with prostaglandin
E2. J. Obstet. Gynaec. Brit. Cwlth. 77 (1970) 200[13J KARIM, S.M.M., G.M.FILSHIE: Therapeutic abor-
tion using F2a. Lancet I (1970) 157[14] KARIM, S. M. M.: On the use of blockers of
prostaglandin synthesis in the control of labor. In:
COCEANI, F., P. M. OLLEY (eds.): Advances in
Prostaglandin and Tromboxane Research, Vol. IV.
Raven Press, New York 1978
[151 LANDESMAN, R., K.H.WILSON: The relaxant
effect of diazoxide on isolated gravid and nongravid
human myometrium. Amer. J. Obstet. Gynec. 101
(1968)120
[16] LAUERSEN, N. H., I. R. MERKATZ, N. TEJANI,
K.H.WILSON, A. ROBERSON, L.I .MANN, F.
FUCHS: Inhibition of premature labor. A multi-
center comparison of ritodrine and ethanol. Amer.
J. Obstet. Gynec. 127 (1977) 837
[17] MANCHESTER, D., H. s. MARGOLIS, R. E.SHEL-
DON: Possible association between maternal indo-
methacin therapy and primary pulmonary hyper-
tension of the newborn. Amer. J. Obstet. Gynec.
126(1976)467
[18] NIEBYL, J. R., D. A. BLAKE, R. D. WHITE, K. M.
KUMOR, N. H. DUBIN, J. C. ROBINSON, P. G.
EGNER: The inhibition of premature labor with
indomethacin. Amer. J. Obstet. Gynec. 136 (1980)
1014
|19) NOVY, M. J., M. J. COOK, L. MANAUGH: Indo-
methacin block of normal onset of parturition in
primates. Amer. J. Obstet. Gynec. 118 (1974) 412|20| REISS, UM J. AT AD, I. RUBINSTEIN, H. ZUCKER-
MAN: The effect of indomethacin in labor at term.
Int. J. Gynec. Obstet. 14 (1976) 369
1211 RUTLAND, A., C. BALLARD: Vaginal prostaglandin
£2 for missed abortion and intrauterine fetal death.
Amer. J.Obstet.Gynec. 128 (1977) 503[22] SHAPIRO, s., v. SISKIND, R. R. MONSON, o. P.
HEINONEN, D.W.KAUFMAN, D. SLONE: Peri-
natal mortality and birth-weight in relation to
aspirin taken during pregnancy. Lancet I (1976)
1375
[23] SHARPE, G.L., B.THALME, K.S.LARSSON: Studies
on closure of the ductus arteriosus. Prostaglandins 8
(1974)363
[24] SHARPE, G.L., K.S.LARSSON, B.THALME: Studies
on closure of the ductus arteriosus. Prostaglandins 9
(1975)585
[25] SPEARING, G.: Alcohol, indomethacin and salbu-
tamol, a comparative trial of their use in preterm
labor. Obstet, and Gynec. 53 (1979) 171
[26J STEER, C. M., R. H. PETRIE: A comparison of
magnesium sulfate and alcohol for the prevention
of premature labor. Amer. J. Obstet. Gynec. 129
(1977)1
[27] WALTMAN, R., v. TRICOMI, A. PALAV: Aspirin
and indomethacin: Effect on instillation-abortion
time of midtrimester hypertonic saline induced
abortion. Prostaglandins 3 (1973) 47
[28] WESSELIUS-DECASPARIS, A., M. TH1ERY, A. Y. L.
SIAN, K. BAUMGARTEN, I. BROSENS, O. GAMIS-
SANS, J. G. STOLK, W. VIVIER: Result of double-
blind multicenter study with ritodrin in premature
labor. Brit. Med. J. 3 (1971) 144
[29] WIQVIST, N., V. LUNDSTROM, K. GREEN: Pre-
mature labour and indomethacin. Prostaglandins 10
(1975)515
[30] ZUCKERMAN, H., U REISS, I.RUBINSTEIN: Inhi-
bition of human premature labor by indomethacin.
Obstet, and Gynec. 44 (1974) 787
[31] ZUCKERMAN, H., U. REISS, J. ATAD, I. LAMPERT,
S.BENEZRA: The effect of indomethacin on plasma
levels of PGF2a in women in labour. Brit. J. Obstet.
Gynaecol. 84 (1975) 339
[32] ZUCKERMAN, H., U. REISS, J. ATAD, I. LAMPERT,
S. BEN EZRA, D. SKLAN: Prostaglandin F2a in
human blood labor. Obstet, and Gynec. 51 (1978)
311
Received April 20, 1983. Accepted May 31, 1983.
Henryk Zuckerman, M. D.
Head of Obstetrics and Gynecology Department
Central Emek Hospital
Afula, Israel
J. Perinat. Med. 12(1984)

